Covid-19 transmission, outcome and associated risk factors in cancer patients at the first month of the pandemic in a Spanish hospital in Madrid

• J. Rogado ^[1] ; B. Obispo ^[1] ; C. Pangua ^[1] ; G. Serrano-Montero ^[1] ; A. Martín Marino ^[1] ; M. Pérez-Pérez ^[1] ; A. López-Alfonso ^[1] ; P. Gullón ^[2] ; M. Á. Lara ^[1]
  1. [1] Hospital Infanta Leonor

     Hospital Infanta Leonor

     Madrid, España

     
  2. [2] Universidad de Alcalá

     Universidad de Alcalá

     Alcalá de Henares, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 12 (December), 2020, págs. 2364-2368
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background There are no large reported series determining the Covid-19 cancer patient’s characteristics. We determine whether differences exist in cumulative incidence and mortality of Covid-19 infection between cancer patients and general population in Madrid.

    Material and methods We reviewed 1069 medical records of all cancer patients admitted at Oncology department between Feb 1 and April 7, 2020. We described Covid-19 cumulative incidence, treatment outcome, mortality, and associated risk factors.

    Results We detected 45/1069 Covid-19 diagnoses in cancer patients vs 42,450/6,662,000 in total population (p < 0.00001). Mortality rate: 19/45 cancer patients vs 5586/42,450 (p = 0.0001). Mortality was associated with older median age, adjusted by staging and histology (74 vs 63.5 years old, OR 1.06, p = 0.03). Patients who combined hydroxychloroquine and azithromycin presented 3/18 deaths, regardless of age, staging, histology, cancer treatment and comorbidities (OR 0.02, p = 0.03).

    Conclusion Cancer patients are vulnerable to Covid-19 with an increase in complications. Combined hydroxychloroquine and azithromycin is presented as a good treatment option.